Effects of social housing condition on chemotherapeutic efficacy in a shionogi carcinoma (SC115) mouse tumor model: Influences of temporal factors, tumor size, and tumor growth rate

Psychosomatic Medicine

Volumn 63, Issue 6, 2001, Pages 973-984

  Kerr, Leslie R ^a   Hundal, Rajinder ^a   Silva, W André ^a   Emerman, Joanne T ^a   Weinberg, Joanne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Psychosocial stress; Shionogi carcinoma; Survival probability; Tumor and host responses

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GROWTH RATE; HOUSING; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHIONOGI CARCINOMA; SOCIAL BEHAVIOR; STATISTICAL ANALYSIS; STRESS; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 0035180995     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-200111000-00017     Document Type: Article

References (92)

1. Psychological stress and breast cancer: The inter-relationship between stress events, coping strategies and personality
2. The Rorschach Interaction Scale as a potential predictor of cancer
3. Coping and psychosocial adaptation: Longitudinal effects over time and stages in breast cancer
4. The prognostic significance of psychosocial factors in women with breast cancer
5. Survival hazards analysis in first recurrent breast cancer patients: Seven-year follow-up
6. Stress and relapse of breast cancer
7. Effect of psychosocial treatment on survival of patients with metastatic breast cancer
8. Psychosocial aspects of breast cancer treatment
9. The role of pharmacogenetics in chemotherapy: Modulation of tumor response and host toxicity
10. Factors involved in clinical pharmacology variability in oncology
11. Patients' use of prevention behaviors in managing side effects related to chemotherapy
12. Physiologic and psychobehavioral research in oncology
13. Stage II breast cancer: Differences between four coping patterns in side effects during adjuvant chemotherapy
14. Stress and the development of breast cancer: A persistent and popular link despite contrary evidence
15. Current theory of psychogenic effects on cancer incidence and prognosis
16. Psychosocial factors and the development of breast cancer: A meta-analysis
17. Stressful life events and onset of breast cancer: Case control study
18. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer
19. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group
20. Identifying priorities of psychosocial need in cancer patients
21. Factors important to psychosocial adjustment to cancer: A review of the evidence
22. Psychological predictors of survival in cancer patients undergoing radiation therapy
23. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy
24. Social relations, social support and survival among patients with cancer
25. Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity
26. Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity
27. Effects of social relationships on survival for women with breast cancer: A prospective study
28. The influence of stressors on the progression of neoplastic change: Mechanisms of carcinogenesis
29. Review of the effects of stress on cancer in laboratory animals: Importance of time of stress application and type of tumor
30. Interactive effects of psychosocial stressors and gender on mouse mammary tumor growth
31. Animal studies of stress and cancer
32. Psychoneuroendocrine influences on immunocompetence and neoplasia
33. Stress and coping factors influence tumor growth
34. Stress and cancer
35. Individual versus group caging of mice with grafted tumors
36. Metastasis and neuroendocrine system in stressed mice
37. Mouse mammary tumors: Alteration of incidence as apparent function of stress
38. Social stress influences tumor growth
39. Effect of housing stress on the formation and development of tumors in rats
40. Effects of psychosocialstressors on mouse mammary tumor growth
41. Effects of social housing condition on the response of the Shionogi mouse mammary carcinoma (SC115) to chemotherapy
42. Survival time in mice bearing TLX5 lymphoma subjected to rotational stress and chemotherapy with CCNU
43. Effects of rotational stress on the effectiveness of cyclophosphamide and razoxane in mice bearing Lewis lung carcinoma
44. Effects of social housing condition and behavior on growth of the Shionogi mouse mammary carcinoma
45. Lethal toxicity of cyclophosphamide depends on the tumor stage studies on the syngeneic adenocarcinoma EO 771 in C57bl/6j mice
46. The effect of timing of a single injection on the toxicity of methotrexate in the rat
47. Interactions between chemotherapeutic drugs and biologic agents
48. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus
49. Circadian rhythms and cancer chemotherapy
50. Classification of dependent and autonomous variants of the Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding
51. Endocrine mediation of psychosocial stress effects on mouse mammary tumor growth
52. Kinetic parameters and growth curves for experimental tumor systems
53. Effects of endocrine regulation of growth of a mouse mammary tumor on its sensitivity to chemotherapy
54. Regression models and life tables
55. Nonparametric estimation from incomplete observations
56. Cancer cell societies and tumor progression
57. Tumor cell societies
58. Melphan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumor
59. Effect of differential housing in mice on natural killer cell activity, tumor growth, and plasma corticosterone
60. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer
61. Length of survival and lymphocyte percentage in women with mammary cancer as a function of psychotherapy
62. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors
63. Stress-induced decline in immune responsiveness in C3H/HeJ mice: Relation to endocrine alterations and tumor growth
64. Apparent ineffectiveness of adriamycin for growth of androgen-dependent Shionogi carcinoma 115 in the mouse
65. Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways
66. Stress, immunity and cancer
67. Influence of corticosteroid hormones on the therapeutic efficacy of cyclophosphamide
68. Alterations in splenic natural killer cell activity induced by the Shionogi mouse mammary tumor
69. Role of natural killer cells in psychosocial stress-induced changes in mouse mammary tumor growth
70. Role of immune and/or natural factors of resistance of the host to tumor progression on the effectiveness of antitumor treatment
71. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer
72. The murine antitumor immune response and its therapeutic manipulation
73. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
74. Enhancement of interleukin-2 release in rats by treatment with bleomycin and Adriamycin in vivo
75. Solid tumor animal model therapeutically predictive for human breast cancer
76. Pathophysiology of cancer cachexia: Current understanding and areas of future research
77. Prognostic effect of weight loss prior to chemotherapy in cancer patients
78. Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use
79. Individual dose adaptation of anticancer drugs
80. Hormonal and metabolic abnormalities in the malnourished cancer patient: Effects on host-tumor interaction
81. Modulation of the toxicity and antitumor activity of alkylating drugs by steroids
82. Use of growthstimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors
83. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: A randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin
84. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin and cisplatin
85. Solid tumor models for assessment of different treatment modalities. XIII. Comparison of response and recovery of host and solid tumor to cyclophosphamide and radiation
86. The temporal dynamics of the stress response
87. The stress response in critical illness
88. Social stress in rats and mice
89. The effect of stress on toxicological investigations
90. Extraordinary potentiation of isoproterenol cardiotoxicity by corticoid pretreatment
91. Glucocorticosteroid interactions with natural toxins: A mini review
92. Stress-the neglected variable in experimental pharmacology and toxicology